Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Diabet Med ; 34(7): 966-972, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28326628

RESUMEN

AIMS: Hyperglycaemic crises (diabetic ketoacidosis and hyperosmolar hyperglycaemic state) are medical emergencies in people with diabetes. We aimed to determine their incidence, recurrence and economic impact. METHODS: An observational study of hyperglycaemic crises cases using the database maintained by the out-of-hospital emergency service, the Healthcare Emergency Public Service (EPES) during 2012. The EPES provides emergency medical services to the total population of Andalusia, Spain (8.5 million inhabitants) and records data on the incidence, resource utilization and cost of out-of-hospital medical care. Direct costs were estimated using public prices for health services updated to 2012. RESULTS: Among 1 137 738 emergency calls requesting medical assistance, 3157 were diagnosed with hyperglycaemic crises by an emergency coordinator, representing 2.9 cases per 1000 persons with diabetes [95% confidence intervals (CI) 2.8 to 3.0]. The incidence of diabetic ketoacidosis was 2.5 cases per 1000 persons with diabetes (95% CI 2.4 to 2.6) and the incidence of hyperosmolar hyperglycaemic state was 0.4 cases per 1000 persons with diabetes (95% CI 0.4 to 0.5). In total, 17.7% (n = 440) of people had one or more hyperglycaemic crisis. The estimated total direct cost was €4 662 151, with a mean direct cost per episode of €1476.8 ± 217.8. CONCLUSIONS: Hyperglycaemic crises require high resource utilization of emergency medical services and have a significant economic impact on the health system.


Asunto(s)
Complicaciones de la Diabetes/terapia , Cetoacidosis Diabética/terapia , Servicios Médicos de Urgencia , Hiperglucemia/terapia , Adolescente , Adulto , Factores de Edad , Anciano , Niño , Costos y Análisis de Costo , Complicaciones de la Diabetes/economía , Complicaciones de la Diabetes/epidemiología , Complicaciones de la Diabetes/fisiopatología , Cetoacidosis Diabética/economía , Cetoacidosis Diabética/epidemiología , Cetoacidosis Diabética/fisiopatología , Costos Directos de Servicios , Registros Electrónicos de Salud , Servicios Médicos de Urgencia/economía , Femenino , Humanos , Hiperglucemia/economía , Hiperglucemia/epidemiología , Hiperglucemia/fisiopatología , Incidencia , Masculino , Recurrencia , Estudios Retrospectivos , Riesgo , Índice de Severidad de la Enfermedad , Factores Sexuales , España/epidemiología
2.
COPD ; 13(1): 93-9, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26418892

RESUMEN

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death globally. In addition to the mortality associated with it, people with COPD experience significant morbidity, making this set of conditions a major public health concern. Infections caused by influenza virus are a preventable cause of morbidity and vaccination has been shown to be effective. The evidence of their benefit in persons with COPD mainly comes from high-income countries where influenza vaccination is used in routine practice, but little is known about the effectiveness, cost-effectiveness, and scalability of vaccination in low- and middle-income countries. We therefore systematically reviewed and present evidence related to vaccination against influenza in persons with COPD with a special focus on studies from low- and middle-income countries (LMICs). Available data from 19 studies suggest that the use of influenza vaccine in persons with COPD is beneficial, cost-effective, and may be relevant for low- and middle-income countries. Wider implementation of this intervention needs to take into account the health care delivery systems of LMICs and use of prevalent viral strains in vaccines to be most cost effective.


Asunto(s)
Países en Desarrollo , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/prevención & control , Enfermedad Pulmonar Obstructiva Crónica/terapia , Análisis Costo-Beneficio , Manejo de la Enfermedad , Humanos , Vacunas contra la Influenza/economía , Gripe Humana/complicaciones , Gripe Humana/economía , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/economía , Resultado del Tratamiento
3.
Diabetes Res Clin Pract ; 198: 110603, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36871877

RESUMEN

BACKGROUND: Older adults with diabetes in the hospital are generally managed similarly to younger adults, however, it is unknown if the degree of frailty can affect glucose control among hospitalized patients. METHODS: We examined glycemic parameters derived from continuous glucose monitoring (CGM) in older adults with type 2 diabetes and frailty who were hospitalized in non-acute settings. Data was pooled from 3 prospective studies using CGM including 97 patients wearing Libre CGM sensors and 166 patients wearing Dexcom G6 CGM. Glycemic parameters (time in range (TIR) 70-180; time below range (TBR) <70 and 54 mg/dl) by CGM were compared between 103 older adults ≥60 years and 168 younger adults <60 years. Frailty was assessed using validated laboratory and vital signs frailty index FI-LAB (n = 85), and its effect on hypoglycemia risk was studied. RESULTS: Older adults, as compared to younger adults, had significantly lower admission HbA1c (8.76% ± 1.82 vs. 10.25% ± 2.29, p < 0.001), blood glucose (203.89 ± 88.65 vs. 247.86 ± 124.17 mg/dl, p = 0.003), mean daily BG (173.9 ± 41.3 vs. 183.6 ± 45.0 mg/dl, p = 0.07) and higher percent TIR 70-180 mg/dl (59.0 ± 25.6% vs. 51.0 ± 26.1%, p = 0.02) during hospital stay. There was no difference in hypoglycemia occurrence between older and younger adults. Higher FI-LAB score was associated with higher % CGM < 70 mg/dl (0.204) and % CGM < 54 mg/dl (0.217). CONCLUSION: Older adults with type 2 diabetes have better glycemic control prior to admission and during hospital stay compared to younger adults. Frailty is associated with longer presence of hypoglycemia in non-acute hospital settings.


Asunto(s)
Diabetes Mellitus Tipo 1 , Diabetes Mellitus Tipo 2 , Fragilidad , Hipoglucemia , Humanos , Anciano , Glucemia , Pacientes Internos , Automonitorización de la Glucosa Sanguínea , Control Glucémico , Estudios Prospectivos , Hipoglucemia/prevención & control , Hipoglucemia/diagnóstico , Envejecimiento , Hipoglucemiantes , Insulina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA